^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Blenrep (belantamab mafodotin-blmf)

    i
    Other names: GSK2857916, J6M0-mcMMAF, GSK 2857916, GSK-2857916, GSK916, GSK-916, GSK 916
    Company:
    GSK, Pfizer
    Drug class:
    Microtubule inhibitor, BCMA-targeted antibody-drug conjugate
    Related drugs:
    2d
    PrE1005: Belantamab Mafodotin or Daratumumab With Bortezomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma (clinicaltrials.gov)
    P3, N=500, Not yet recruiting, PrECOG, LLC.
    New P3 trial
    |
    lenalidomide • bortezomib • Darzalex Faspro (daratumumab and hyaluronidase-fihj) • Blenrep (belantamab mafodotin-blmf)
    3d
    ALANIS: A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Cyclophosphamide, Bortezomib, and Dexamethasone in Adult Participants With Newly Diagnosed Amyloid Light Chain (AL) Amyloidosis (clinicaltrials.gov)
    P2, N=60, Not yet recruiting, GlaxoSmithKline | Trial completion date: Oct 2031 --> Feb 2032 | Initiation date: Dec 2025 --> Mar 2026 | Trial primary completion date: Apr 2027 --> Aug 2027
    Trial completion date • Trial initiation date • Trial primary completion date
    |
    bortezomib • cyclophosphamide • Blenrep (belantamab mafodotin-blmf)
    4d
    Study of Belantamab Mafodotin as Pre- and Post-autologous Stem Cell Transplant and Maintenance for Multiple Myeloma (clinicaltrials.gov)
    P2, N=41, Active, not recruiting, University of Pennsylvania | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    melphalan • Blenrep (belantamab mafodotin-blmf)
    15d
    DREAMM 13: A Study of Belantamab Mafodotin in Multiple Myeloma Participants With Normal and Impaired Hepatic Function (clinicaltrials.gov)
    P1, N=0, Withdrawn, GlaxoSmithKline | N=28 --> 0 | Recruiting --> Withdrawn
    Enrollment change • Trial withdrawal
    |
    Blenrep (belantamab mafodotin-blmf)
    30d
    GEM-BELA-VRd: Belantamab Mafodotin in Newly Diagnosed Transplant Eligible Multiple Myeloma Patients (clinicaltrials.gov)
    P2, N=50, Active, not recruiting, PETHEMA Foundation | Recruiting --> Active, not recruiting | Trial completion date: Jul 2025 --> Dec 2025
    Enrollment closed • Trial completion date
    |
    lenalidomide • bortezomib • dexamethasone • melphalan • Blenrep (belantamab mafodotin-blmf)
    1m
    Belantamab Mafodotin and Lenalidomide for the Treatment of Multiple Myeloma in Patients With Minimal Residual Disease Positive After Stem Cell Transplant (clinicaltrials.gov)
    P2, N=20, Suspended, Roswell Park Cancer Institute | Recruiting --> Suspended
    Trial suspension • Minimal residual disease
    |
    lenalidomide • Blenrep (belantamab mafodotin-blmf)
    1m
    A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM) (clinicaltrials.gov)
    P2, N=200, Not yet recruiting, GlaxoSmithKline
    New P2 trial
    |
    bortezomib • carfilzomib • dexamethasone • pomalidomide • Blenrep (belantamab mafodotin-blmf)
    1m
    Belantamab Mafadotin Maintenance Therapy After Salvage Autologous Hematopoietic Cell Transplantation in Patients With Relapse Refractory Multiple Myeloma (clinicaltrials.gov)
    P1, N=6, Terminated, M.D. Anderson Cancer Center | Trial completion date: May 2027 --> Nov 2025 | Active, not recruiting --> Terminated | Trial primary completion date: May 2027 --> Nov 2025; <75% participation
    Trial completion date • Trial termination • Trial primary completion date
    |
    CD4 (CD4 Molecule)
    |
    Blenrep (belantamab mafodotin-blmf)
    1m
    DREAMM 5: Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) (clinicaltrials.gov)
    P2, N=208, Active, not recruiting, GlaxoSmithKline | Trial completion date: Feb 2029 --> Mar 2027 | Trial primary completion date: Feb 2029 --> Apr 2025
    Trial completion date • Trial primary completion date
    |
    lenalidomide • Jemperli (dostarlimab-gxly) • dexamethasone • pomalidomide • Sarclisa (isatuximab-irfc) • Blenrep (belantamab mafodotin-blmf) • Ogsiveo (nirogacestat) • feladilimab (GSK3359609) • GSK3174998
    1m
    ALANIS: A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Cyclophosphamide, Bortezomib, and Dexamethasone in Adult Participants With Newly Diagnosed Amyloid Light Chain (AL) Amyloidosis (clinicaltrials.gov)
    P2, N=60, Not yet recruiting, GlaxoSmithKline
    New P2 trial
    |
    bortezomib • cyclophosphamide • Blenrep (belantamab mafodotin-blmf)
    2ms
    SOHO State of the Art Updates and Next Questions | Treatment of Myeloma Early Relapse: Non-CAR T Cell. (PubMed, Clin Lymphoma Myeloma Leuk)
    The main determinant of second-line therapy selection includes refractoriness, particularly to lenalidomide and anti-CD38 monoclonal antibodies, followed by cytogenetic risk, relapse aggressiveness, frailty, and patient preferences...Combinations based on belantamab mafadotin, an antibody drug conjugate targeting B cell maturation antigen (BCMA), are currently the leading non CAR-T options in this setting, while exportin-1 inhibitors, such as selinexor, and next-generation proteasome inhibitors offer additional options. Ongoing trials assessing T-cell redirecting bispecific antibodies targeting B cell maturation antigen or GPRC5D may further improve outcomes at first relapse as access and safety profiles evolve. In conclusion, early-relapse multiple myeloma care should be individualized in order to optimize patient outcomes and achieve long-term remissions with acceptable toxicity profile.
    Review • Journal
    |
    XPO1 (Exportin 1)
    |
    lenalidomide • Xpovio (selinexor) • Blenrep (belantamab mafodotin-blmf)
    2ms
    Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Isatuximab in Participants With RRMM (clinicaltrials.gov)
    P1/2, N=30, Active, not recruiting, GlaxoSmithKline
    New P1/2 trial
    |
    Sarclisa (isatuximab-irfc) • Blenrep (belantamab mafodotin-blmf)